

STATE OF NEW YORK

1193--C

2019-2020 Regular Sessions

IN ASSEMBLY

January 14, 2019

Introduced by M. of A. PAULIN, COOK, CYMBROWITZ, ABINANTI, GUNTHER, WEPRIN, HEVESI, RYAN, STIRPE, BUCHWALD, DiPIETRO, BRABENEC, BLAKE, FAHY, ORTIZ, COLTON, NORRIS, BARRETT, PHEFFER AMATO, DINOWITZ, LALOR, ZEBROWSKI, STECK, HUNTER, BRONSON, SOLAGES, PEOPLES-STOKES, DE LA ROSA, B. MILLER, GARBARINO, MORINELLO, FITZPATRICK, DICKENS, MAGNARELLI, PICHARDO, SANTABARBARA, GIGLIO, D. ROSENTHAL, KIM, RODRIGUEZ, ABBATE, JONES, ARROYO, VANEL, McDONOUGH, AUBRY, L. ROSENTHAL, ENLEBRIGHT, LAVINE, D'URSO, JAFFEE, JOYNER, SEAWRIGHT, M. L. MILLER, FERNANDEZ, FALL, BURKE, REILLY, REYES, SALKA, WALLACE, JACOBSON, JEAN-PIERRE, MOSLEY, MANKTELOW, TAYLOR, BENEDETTO, STERN, GRIFFIN, BUTTENSCHON, MALLIOTAKIS, EICHENSTEIN -- Multi-Sponsored by -- M. of A. BARCLAY, BLANKENBUSH, CAHILL, CARROLL, CROUCH, CUSICK, DAVILA, EPSTEIN, FRIEND, GALEF, GOODELL, GOTTFRIED, HAWLEY, LENTOL, LIFTON, LUPARDO, PALMESANO, PERRY, QUART, RIVERA, SIMOTAS, STEC, TAGUE, THIELE, WALSH, WOERNER, WRIGHT -- read once and referred to the Committee on Higher Education -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee -- again reported from said committee with amendments, ordered reprinted as amended and recommitted to said committee -- again reported from said committee with amendments, ordered reprinted as amended and recommitted to said committee

AN ACT to amend the education law, in relation to the use of oral medications by optometrists

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

- 1 Section 1. Paragraph (e) of subdivision 1 of section 7101-a of the
- 2 education law, as added by chapter 517 of the laws of 1995, is amended
- 3 to read as follows:
- 4 (e) [~~Phase one~~] Topical therapeutic pharmaceutical agents. [~~Phase one~~]
- 5 Topical therapeutic pharmaceutical agents shall mean those drugs which

EXPLANATION--Matter in italics (underscored) is new; matter in brackets [~~-~~] is old law to be omitted.

LBD01275-10-0

shall be limited to topical application to the surface of the eye for therapeutic purposes and shall be limited to:

- (i) antibiotic/antimicrobials;
- (ii) decongestants/anti-allergens;
- (iii) non-steroidal anti-inflammatory agents;
- (iv) steroidal anti-inflammatory agents;
- (v) antiviral agents;
- (vi) hyperosmotic/hypertonic agents;
- (vii) cycloplegics;
- (viii) artificial tears and lubricants; and
- (ix) immunosuppressive agents.

§ 2. Paragraph (f) of subdivision 1 of section 7101-a of the education law, as added by chapter 517 of the laws of 1995, is amended to read as follows:

(f) ~~[Phase two therapeutic]~~ Therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension. ~~[Phase two]~~ Therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension shall mean those drugs which shall be limited to topical application to the surface of the eye and shall be limited to:

- (i) beta blockers;
- (ii) alpha agonists;
- (iii) direct acting cholinergic agents;
- (iv) prostaglandin analogs; and
- (v) carbonic anhydrase inhibitors.

§ 3. Subdivision 1 of section 7101-a of the education law is amended by adding a new paragraph (g) to read as follows:

(g) Oral therapeutic pharmaceutical agents. Oral therapeutic pharmaceutical agents shall mean those orally administered drugs used for therapeutic purposes solely for the treatment of diseases of the eye and adnexa and shall be limited to:

(i) the following antibiotics:

- (1) amoxicillin/clavulanate potassium;
- (2) cephalexin;
- (3) azithromycin;
- (4) sulfamethoxazole/trimethoprim;
- (5) doxycycline; and
- (6) tetracycline;

(ii) the following antiglaucoma agents used for the management of acute increases in intraocular pressure; provided, however, an optometrist may use or prescribe a maximum of one twenty-four hour prescription and shall immediately refer the patient to a licensed physician specializing in diseases of the eye:

- (1) acetazolamide; and
- (2) methazolamide; and

(iii) the following antiviral agents used for herpes zoster ophthalmicus; provided an optometrist shall use or prescribe in maximum, one seven-day prescription; provided, however, if a patient is diagnosed with herpes zoster ophthalmicus and has not already been examined by a primary care physician or other appropriate physician for such viral condition, an optometrist shall refer the patient to a licensed primary care physician, licensed physician specializing in diseases of the eye, or other appropriate physician within three days of such diagnosis:

- (1) valacyclovir; and
- (2) acyclovir.

§ 4. The subdivision heading and paragraph (a) of subdivision 4 of section 7101-a of the education law, as added by chapter 517 of the laws of 1995, are amended to read as follows:

~~[Phase one]~~ Topical therapeutic pharmaceutical agents. (a) Before using or prescribing ~~[phase one]~~ topical therapeutic pharmaceutical agents, each optometrist shall have completed at least three hundred hours of clinical training in the diagnosis, treatment and management of patients with ocular disease other than glaucoma and ocular hypertension, not fewer than twenty-five hours of such training shall have been completed subsequent to June thirtieth, nineteen hundred ninety-three and additionally shall either have taken and successfully passed the treatment and management of ocular diseases portion of the National Board of Examiners in Optometry test or have taken and successfully passed an examination acceptable to the board.

§ 5. Paragraph (b) of subdivision 4 of section 7101-a of the education law, as added by chapter 517 of the laws of 1995, is amended to read as follows:

(b) Before using or prescribing ~~[phase two]~~ therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension, an optometrist must be certified for diagnostic and ~~[phase one]~~ topical therapeutic agents and have completed an additional one hundred hours of clinical training in the diagnosis, treatment and management of patients with glaucoma and ocular hypertension, not fewer than twenty-five hours of such training shall have been completed subsequent to July first, nineteen hundred ninety-four, and shall have taken and successfully passed an oral or written examination acceptable by the board.

§ 6. Paragraphs (c) and (d) of subdivision 4 of section 7101-a of the education law are relettered paragraphs (d) and (e) and a new paragraph (c) is added to read as follows:

(c) Before using or prescribing oral therapeutic pharmaceutical agents, an optometrist must be certified to prescribe diagnostic pharmaceutical agents and topical therapeutic and therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension, have completed an oral therapeutic pharmaceutical agent certification course and have passed an examination within five years of the department's approval of the initial certification course or the initial examination, whichever is later provided, however, an optometrist who has commenced the oral therapeutic pharmaceutical agent certification course within the five year time period but has not yet passed an examination shall be allowed to take such examination and become certified after the five year time period provided for in this paragraph has ended.

(i) The curriculum for the oral therapeutic pharmaceutical agent certification course shall include, but not be limited to, instruction in pharmacology and drug interaction in treating ocular disease and be taught through clinical case scenarios and emphasize clinical decision making and shall be no less than forty hours, of which no less than twenty-four hours shall be live instruction.

(ii) Such course shall qualify towards meeting the continuing education per triennial registration requirement pursuant to subdivision seven of this section.

(iii) The examination shall assess the knowledge of materials in the curriculum and reflect the oral therapeutic pharmaceutical agents described in paragraph (g) of subdivision one of this section, and shall be acceptable to the department.

(iv) The initial, and any subsequent, curriculum and examination shall be subject to review and approval by the department.

(v) The requirement for the oral therapeutic pharmaceutical agent certification course and examination shall not apply to those optometrists who graduated from an accredited college of optometry subsequent to January first, two thousand twenty-one and have taken and successfully passed the National Board of Examiners in Optometry examination or an examination acceptable to the department.

§ 7. Subdivision 5 of section 7101-a of the education law, as added by chapter 517 of the laws of 1995, is amended to read as follows:

5. Suspension of certification. The department shall suspend the certification for the use and prescribing of ~~[phase one]~~ topical therapeutic agents of any optometrist who fails to receive certification for ~~[phase two]~~ therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension within three years of having been certified for ~~[phase one]~~ topical therapeutic pharmaceutical agents.

§ 8. The subdivision heading of subdivision 6 of section 7101-a of the education law, as added by chapter 517 of the laws of 1995, is amended to read as follows:

Consultation with use of certain topical therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension.

§ 9. Subdivision 7 of section 7101-a of the education law, as added by chapter 517 of the laws of 1995, is amended to read as follows:

7. Continuing education. (a) Each optometrist certified to use ~~[phase one or phase two]~~ topical therapeutic pharmaceutical agents and therapeutic pharmaceutical agents for treatment of glaucoma and ocular hypertension, shall complete a minimum of thirty-six hours of continuing education in the area of ocular disease and pharmacology per triennial registration period. ~~[The education shall be in the area of ocular disease and pharmacology and may include both didactic and clinical components.]~~ Each optometrist certified to use oral therapeutic pharmaceutical agents shall, in addition to the minimum thirty-six hours of continuing education provided for in this subdivision, complete an additional minimum of eighteen hours of continuing education related to systemic disease and therapeutic treatment per triennial registration period. Such educational programs may include both didactic and clinical components and shall be approved in advance by the department ~~[and evidence of the completion of this requirement shall be submitted with each application for license renewal as required by section sixty five hundred two of this chapter]~~. Beginning on January first, two thousand twenty-two, all sponsors of continuing education courses seeking advanced approval from the department shall file an application and pay a fee determined by the department in accordance with the regulations of the commissioner. An optometrist subject to the provisions of this subdivision whose first registration date following the effective date of this section occurs less than three years from such effective date, but on or after January first, two thousand twenty-two, shall complete continuing education hours on a prorated basis at the rate of one hour per month for the period beginning January first, two thousand twenty-two up to the first registration date thereafter. An optometrist who has not satisfied the mandatory continuing education requirement pursuant to this subdivision shall not be issued a triennial registration certificate by the department and shall not practice unless and until a conditional registration is issued as provided for in paragraph (b) of this subdivision. Continuing education hours taken during one triennium may not be transferred to the subsequent triennium.

(b) The department, in its discretion, may issue a conditional registration to an optometrist who fails to meet the continuing education

1 requirements established in paragraph (a) of this subdivision, but who
2 agrees to make up any deficiencies and complete any additional education
3 which the department may require. The fee for such a conditional regis-
4 tration shall be the same as, and in addition to, the fee for the trien-
5 nial registration. The duration of such conditional registration shall
6 be determined by the department, but shall not exceed one year. Any
7 optometrist who is notified of the denial of registration for failure to
8 submit evidence, satisfactory to the department, of required continuing
9 education and who practices without such registration may be subject to
10 disciplinary proceedings pursuant to section sixty-five hundred ten of
11 this title.

12 (c) In accordance with the intent of this section, adjustment to the
13 mandatory continuing education requirement may be granted by the depart-
14 ment for reasons of health that are certified by an appropriate health
15 care professional, for extended active duty with the armed forces of the
16 United States, or for other good cause acceptable to the department
17 which may prevent compliance.

18 (d) An optometrist not engaged in practice, as determined by the
19 department, shall be exempt from the mandatory continuing education
20 requirement upon the filing of a statement with the department declaring
21 such status. Any licensee who returns to the practice of optometry
22 during the triennial registration period shall notify the department
23 prior to reentering the profession and shall meet such continuing educa-
24 tion requirements as shall be prescribed by regulations of the commis-
25 sioner.

26 (e) Optometrists subject to the provisions of this subdivision shall
27 maintain adequate documentation of completion of acceptable continuing
28 education credits and shall provide such documentation at the request of
29 the department. Failure to provide such documentation upon the request
30 of the department shall be an act of misconduct subject to disciplinary
31 proceedings pursuant to section sixty-five hundred ten of this title.

32 (f) The mandatory continuing education fee shall be determined by the
33 department. Such fee shall be payable on or before the first day of
34 each triennial registration period, and shall be paid in addition to the
35 triennial registration fee required by subdivision eight of section
36 seventy-one hundred four of this article.

37 § 10. The subdivision heading and subparagraph (i) of paragraph (a) of
38 subdivision 8 of section 7101-a of the education law, as added by chap-
39 ter 517 of the laws of 1995, are amended to read as follows:

40 Notice to patient with the use or prescription of topical therapeutic
41 pharmaceutical agents and therapeutic pharmaceutical agents for treat-
42 ment of glaucoma and ocular hypertension.

43 (i) An optometrist prescribing topical steroids or antiviral medica-
44 tion shall inform each patient that in the event the condition does not
45 improve within five days, a physician of the patient's choice will be
46 notified.

47 § 11. Subdivision 10 of section 7101-a of the education law, as added
48 by chapter 517 of the laws of 1995, is amended to read as follows:

49 10. Pharmaceutical agents. Optometrists who have been approved and
50 certified by the department shall be permitted to use the following
51 drugs:

52 (a) Diagnostic pharmaceuticals.

53 (b) Those optometrists having been certified for [~~phase one~~] topical
54 therapeutic pharmaceutical agents shall be authorized [(i) to use and
55 recommend all nonprescription medications appropriate for ocular disease
56 whether intended for topical or oral use; and (ii)] to use and prescribe

1 all [~~phase one~~] topical therapeutic pharmaceutical agents specified in
2 paragraph (e) of subdivision one of this section, which are FDA approved
3 and commercially available for topical use.

4 In the event an optometrist treats a patient with topical antiviral or
5 steroidal drugs and the patient's condition either fails to improve or
6 worsens within five days, the optometrist shall notify a physician
7 designated by the patient or, if none, by the treating optometrist.

8 (c) Those optometrists having been certified for [~~phase two~~] therapeu-
9 tic pharmaceutical agents for treatment of glaucoma and ocular hyperten-
10 sion shall be authorized to use and prescribe [~~phase two~~] therapeutic
11 pharmaceutical agents for treatment of glaucoma and ocular hypertension
12 specified in paragraph (f) of subdivision one of this section, which are
13 FDA approved and commercially available.

14 (d) Those optometrists having been certified for oral therapeutic
15 pharmaceutical agents shall be authorized to use and prescribe oral
16 therapeutic pharmaceutical agents specified in paragraph (g) of subdivi-
17 sion one of this section, which are FDA approved and commercially avail-
18 able and shall comply with all safety information and side-effect and
19 warning advisories contained in the most current physicians' desk refer-
20 ence.

21 (e) Those optometrists having been certified for topical therapeutic
22 pharmaceutical agents, therapeutic pharmaceutical agents for treatment
23 of glaucoma and ocular hypertension or oral therapeutic pharmaceutical
24 agents shall be authorized to use and recommend all nonprescription
25 medications, whether intended for topical or oral use, appropriate for
26 the treatment of the eye and adnexa.

27 § 12. Subdivision 8 of section 7104 of the education law, as amended
28 by chapter 517 of the laws of 1995, is amended to read as follows:

29 (8) Fees: pay a fee of two hundred twenty dollars to the department
30 for admission to a department conducted examination and for an initial
31 license, a fee of one hundred fifteen dollars for each reexamination, a
32 fee of one hundred thirty-five dollars for an initial license for
33 persons not requiring admission to a department conducted examination,
34 [~~and~~] a fee of two hundred ten dollars for each triennial registration
35 period, [~~and~~] for additional authorization for the purpose of utilizing
36 diagnostic pharmaceutical agents, a fee of sixty dollars, and for
37 certification to use or prescribe oral therapeutic pharmaceutical
38 agents, a fee of two hundred fifty dollars.

39 § 13. This act shall take effect two years after it shall have become
40 a law; provided that section nine of this act shall take effect January
41 1, 2022. Effective immediately, the addition, amendment and/or repeal
42 of any rule or regulation necessary for the implementation of this act
43 on its effective date are authorized and directed to be made and
44 completed on or before such effective date.